Denamarin

Verify with FDA CVM →

386 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
386
Total Reports
64
Deaths Reported
1660.0%
Death Rate

Active Ingredients

Denamarin

Administration Routes

OralUnknownSubcutaneous

Species Affected

Dog 370
Cat 16

Most Affected Breeds

Retriever - Labrador 49
Chihuahua 22
Beagle 18
Crossbred Canine/dog 16
Retriever - Golden 15
Terrier - Bull - American Pit 13
Shepherd Dog - German 11
Domestic Shorthair 11
Terrier (unspecified) 10
Sheepdog - Shetland 9

Most Reported Reactions

Elevated alanine aminotransferase (ALT) 65
Vomiting 64
Lethargy (see also Central nervous system depression in Neurological) 62
Diarrhoea 52
Death by euthanasia 45
Polydipsia 41
Polyuria 33
Elevated serum alkaline phosphatase (SAP) 32
Elevated serum alkaline phosphatase (ALP) 30
Not eating 26
Anorexia 26
Seizure NOS 26

Outcome Breakdown

Ongoing
215 (55.7%)
Outcome Unknown
70 (18.1%)
Euthanized
45 (11.7%)
Recovered/Normal
37 (9.6%)
Died
19 (4.9%)

Data Summary

Metric Value
Total adverse event reports 386
Reports involving death 64
Case-fatality rate (reported events) 1660.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Denamarin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 386 adverse event reports referencing Denamarin, including 64 reports in which the animal died — a 1660.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Denamarin. Reported administration routes include Oral, Unknown, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Denamarin reports are Dog (370 reports), Cat (16 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (49), Chihuahua (22), Beagle (18) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Denamarin are Elevated alanine aminotransferase (ALT) (65), Vomiting (64), Lethargy (see also Central nervous system depression in Neurological) (62), Diarrhoea (52). Of the 386 reports with a coded outcome, Ongoing is the leading category at 55.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Denamarin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial